The effect of a novel transition state inhibitor of methylthioadenosine phosphorylase on pemetrexed activity

被引:15
作者
Chattopadhyay, Shrikanta
Zhao, Rongbao
Tsai, Eugenia
Schramm, Vern L.
Goldman, I. David
机构
[1] Yeshiva Univ Albert Einstein Coll Med, Dept Med & Mol Pharmacol, Bronx, NY 10461 USA
[2] Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA
关键词
D O I
10.1158/1535-7163.MCT-06-0313
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pemetrexed is a new-generation antifolate inhibitor of thymidylate synthase (TS) and a weaker inhibitor of glycinamide ribonucleotide transformylase (GARFT) required for de novo purine synthesis. Methylthioadenosine phosphorylase (MTAP) salvages purines by releasing adenine from methylthioadenosine and is often deleted in mesothelioma. The current study addresses the effect of MTAP on pemetrexed activity using a highly potent transition state inhibitor of MTAP, MT-DADMe-Immucillin A (ImmA; K-i = 86 pmol/L) in the MTAP(+) NCI-H28 and MTAP(-) NCI-H2052 mesothelioma cell lines. Based on selective nucleoside protection, TS was found to be the primary pemetrexed target in both cell lines with GARFT inhibition requiring 20- to 30-fold higher pemetrexed concentrations. ImmA had no effect on pernetrexed activity but, when thymidine was added, the pemetrexed IC50 decreased by a factor of similar to 3 in MTAP(+) H28 cells with no effect in MTAP(-) H2052 cells. Conversely, the transfection of MTAP into H2052 cells increased the pemetrexed IC50 by nearly 3-fold but only in the presence of thymidine; this was reversed by ImmA. An MTAP-specific short interfering RNA produced a 2-fold decrease in pemetrexed IC50 in MTAP(+) HeLa cells in the presence of thymidine. These data indicate that suppression of constitutive MTAP has no effect on pemetrexed activity when the primary target is TS. There is a modest salutary effect when the pernetrexed target is GARFT alone.
引用
收藏
页码:2549 / 2555
页数:7
相关论文
共 28 条
  • [1] Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent
    Adjei, AA
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (12) : 4276S - 4280S
  • [2] ALLEGRA CJ, 1986, J BIOL CHEM, V261, P6478
  • [3] Batova A, 1999, CANCER RES, V59, P1492
  • [4] Frequent deletion in the methylthioadenosine phosphorylase gene in T-cell acute lymphoblastic leukemia: Strategies for enzyme-targeted therapy
    Batova, A
    Diccianni, MB
    Nobori, T
    Vu, T
    Yu, J
    Bridgeman, L
    Yu, AL
    [J]. BLOOD, 1996, 88 (08) : 3083 - 3090
  • [5] Characterization of methylthioadenosin, phosphorylase (MTAP) expression in malignant melanoma
    Behrmann, I
    Wallner, S
    Komyod, W
    Heinrich, PC
    Schuierer, M
    Buettner, R
    Bosserhoff, AK
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2003, 163 (02) : 683 - 690
  • [6] The inverse relationship between reduced folate carrier function and Pemetrexed activity in a human colon cancer cell line
    Chattopadhyay, S
    Zhao, RB
    Krupenko, SA
    Krupenko, N
    Goldman, DI
    [J]. MOLECULAR CANCER THERAPEUTICS, 2006, 5 (02) : 438 - 449
  • [7] Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells
    Chen, VJ
    Bewley, JR
    Andis, SL
    Schultz, RM
    Iversen, PW
    Shih, C
    Mendelsohn, LG
    Seitz, DE
    Tonkinson, JL
    [J]. BRITISH JOURNAL OF CANCER, 1998, 78 (Suppl 3) : 27 - 34
  • [8] Expression of methylthioadenosine phosphorylase cDNA in p16(-), MTAP(-) malignant cells: Restoration of methylthioadenosine phosphorylase-dependent salvage pathways and alterations of sensitivity to inhibitors of purine de novo synthesis
    Chen, ZH
    Olopade, OI
    Savarese, TM
    [J]. MOLECULAR PHARMACOLOGY, 1997, 52 (05) : 903 - 911
  • [9] Chen ZH, 1996, CANCER RES, V56, P1083
  • [10] Methylthioadenosine phosphorylase gene deletions are frequently detected by fluorescence in situ hybridization in conventional chondrosarcomas
    Chow, WA
    Victoria, B
    Gaytan, P
    Borden, E
    Goldblum, J
    Hicks, D
    Slovak, ML
    [J]. CANCER GENETICS AND CYTOGENETICS, 2006, 166 (02) : 95 - 100